论文部分内容阅读
目的探讨抗肿瘤血管生成联合介入治疗中晚期肝癌的临床疗效。方法选取2009年5月～2012年5月我院收治139例中晚期肝癌患者的临床资料进行回顾性分析,按照随机数字表法将其分为观察组72例(抗肿瘤血管生成联合介入化疗)和对照组(仅接受介入化疗)67例,对两组患者的临床疗效和Kamofsky评分进行比较分析。结果 (1)观察组的CR+PR率为43.1%明显高于对照组28.4%,两组比较差异有统计学意义(P<0.05);(2)两组患者在Kamofsky评分比较,观察组的Kamofsky评分明显高于对照组,差异有统计学意义(P<0.05)。结论抗肿瘤血管生成联合介入治疗中晚期肝癌能有效改善患者生活质量,延长患者生存时间,为治疗肝癌非手术的首选方法。
Objective To investigate the clinical efficacy of anti-tumor angiogenesis combined with interventional treatment of advanced liver cancer. Methods The clinical data of 139 patients with advanced hepatocellular carcinoma treated in our hospital from May 2009 to May 2012 were retrospectively analyzed. According to the random number table, they were divided into observation group (n = 72) (anti-tumor angiogenesis combined with interventional chemotherapy) And control group (only received chemotherapy) in 67 cases. The clinical efficacy and Kamofsky score of two groups were compared. Results (1) The CR + PR rate in the observation group was significantly higher than that in the control group (43.1% vs 28.4%, P <0.05). (2) Compared with the Kamofsky score in the two groups, Kamofsky score was significantly higher than the control group, the difference was statistically significant (P <0.05). Conclusion Anti-tumor angiogenesis combined with interventional treatment of advanced hepatocellular carcinoma can effectively improve the quality of life of patients and prolong the survival time of patients. It is the first choice for non-surgical treatment of liver cancer.